Aurobindo Pharma's US subsidiary recieved U.S. Federal Trade Commission (FTC) approval to proceed with the acquisition of Lannett Company LLC in a deal valued at $250 million, the company announced on Monday.
The acquisition would be carried out on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026. The transaction is expected to be immediately accretive to Aurobindo Group’s earnings per share, it said in a regulatory filing.